Figure 3
Figure 3. Complete clinical response and T-cell responses in patient number 2. (A-B) PET/CT scans taken before start of treatment and at 8 months. (C) CT from before treatment and at 1 year. (D) Flow cytometric measurements of antitumor CD8+ T-cell responses in peripheral blood drawn before treatment and at 2 months postvaccination, following 5 days of coculture with autologous T cells. Upper dot plots: Percent proliferating cells, measured as CD3+CD8+CD20– events showing low CFSE fluorescence. Lower dot plots: On day 5, cocultures of MNCs and tumor cells were restimulated with autologous tumor cells for 5 hours before measuring degranulation (CD107 a/b expression) and secretion of IFN-γ. Numbers represent percent responding cells.

Complete clinical response and T-cell responses in patient number 2. (A-B) PET/CT scans taken before start of treatment and at 8 months. (C) CT from before treatment and at 1 year. (D) Flow cytometric measurements of antitumor CD8+ T-cell responses in peripheral blood drawn before treatment and at 2 months postvaccination, following 5 days of coculture with autologous T cells. Upper dot plots: Percent proliferating cells, measured as CD3+CD8+CD20 events showing low CFSE fluorescence. Lower dot plots: On day 5, cocultures of MNCs and tumor cells were restimulated with autologous tumor cells for 5 hours before measuring degranulation (CD107 a/b expression) and secretion of IFN-γ. Numbers represent percent responding cells.

Close Modal

or Create an Account

Close Modal
Close Modal